Disc Medicine CEO sells 33K shares after option exercise
Disc Medicine, Inc. (IRON) CEO and director John D. Quisel reported an option exercise and related share sales.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Disc Medicine, Inc. (IRON) CEO and director John D. Quisel reported an option exercise and related share sales. On August 17, 2026, he exercised a stock option for 33,000 shares of common stock at an exercise price of $13.50 per share, reducing that option position to rights over 91,586 shares, with the option expiring on December 28, 2032. The same day, he sold an aggregate of 33,000 common shares in three open-market transactions at weighted average prices of $78.1061, $79.1952, and $79.8420 per share, each over stated price ranges. All transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026.
Insider Trade Summary 10b5-1
Exercise and Sale: 33,000 shares ($2.17M approx. pre-tax spread)
Exercise and Sale
5 txns
Insider
Quisel John D
Role
Chief Executive Officer
Sold
33,000 shs ($2.61M)
Approx. gross sale proceeds
$2.61M
Approx. exercise cost
$446K
Approx. pre-tax spread
$2.17M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F5 | 33,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 33,000 | $13.50 | $446K |
| Sale | Common Stock F1, F2 | 8,400 | $78.1061 | $656K |
| Sale | Common Stock F1, F3 | 12,712 | $79.1952 | $1.01M |
| Sale | Common Stock F1, F4 | 11,888 | $79.842 | $949K |
Holdings After Transaction:
Stock Option (Right to Buy) — 91,586 contracts (Direct);
Common Stock — 226,064 shares (Direct)
Footnotes (5)
- F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.50 to $78.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.53 to $79.52, inclusive.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.53 to $80.02, inclusive.
- F5. The shares underlying this option vest in 48 equal monthly installments following December 29, 2022, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Options Exercised: 33,000 shares
Option Exercise Price: $13.50 per share
Common Shares Sold (Total): 33,000 shares
+5 more
8 metrics
Options Exercised
33,000 shares
Stock Option (Right to Buy) exercised into common stock on August 17, 2026
Option Exercise Price
$13.50 per share
Exercise price for 33,000-stock-option derivative security
Common Shares Sold (Total)
33,000 shares
Aggregate of three open-market sales of Disc Medicine common stock
Sale Price 1 (Weighted Average)
$78.1061 per share
First sale of 8,400 shares; trades ranged from $77.50 to $78.49
Sale Price 2 (Weighted Average)
$79.1952 per share
Second sale of 12,712 shares; trades ranged from $78.53 to $79.52
Sale Price 3 (Weighted Average)
$79.8420 per share
Third sale of 11,888 shares; trades ranged from $79.53 to $80.02
Remaining Option Position
91,586 shares
Total shares underlying the option following the exercise transaction
Option Expiration Date
December 28, 2032
Expiration date of the Stock Option (Right to Buy)
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), vesting
4 terms
Rule 10b5-1 trading plan regulatory
"transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
vesting financial
"shares underlying this option vest in 48 equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did IRON CEO John D. Quisel report in this Form 4?
John D. Quisel reported exercising 33,000 stock options for Disc Medicine, Inc. (IRON) common shares at $13.50 per share and selling 33,000 shares of common stock in three open-market transactions on August 17, 2026.
What stock option did the IRON CEO exercise in this filing?
He exercised a Stock Option (Right to Buy) for 33,000 Disc Medicine common shares at an exercise price of $13.50 per share. After this transaction, the option represents rights over 91,586 underlying common shares and expires on December 28, 2032.
Were the IRON CEO’s trades made under a Rule 10b5-1 trading plan?
Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026, indicating the trades were pre-arranged under that plan rather than timed discretionarily.
How do the footnotes describe the sale prices for the IRON stock transactions?
Each sale’s reported price is a weighted average price. The footnotes state the shares were sold in multiple transactions within ranges from $77.50 up to $80.02 per share and that full breakdowns are available upon request.
What is the vesting schedule of the option referenced in the IRON Form 4?
The option’s underlying shares vest in 48 equal monthly installments following December 29, 2022, subject to John D. Quisel’s continued service on each vesting date, as described in the filing’s footnotes.
AI-generated analysis. How Rhea-AI works. Not financial advice.
